MA37500B1 - Formulation parentérale d'esmolol - Google Patents
Formulation parentérale d'esmololInfo
- Publication number
- MA37500B1 MA37500B1 MA37500A MA37500A MA37500B1 MA 37500 B1 MA37500 B1 MA 37500B1 MA 37500 A MA37500 A MA 37500A MA 37500 A MA37500 A MA 37500A MA 37500 B1 MA37500 B1 MA 37500B1
- Authority
- MA
- Morocco
- Prior art keywords
- esmolol hydrochloride
- ready
- parenteral formulation
- pure
- solvent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne une formulation parentérale de chlorhydrate d'esmolol pour son utilisation dans le traitement d'un patient souffrant de tachycardie qui comprend une poudre lyophilisée constituée de chlorhydrate d'esmolol pur, ladite poudre étant reconstituée pour obtenir une solution i.V. Prête à l'emploi de chlorhydrate d'esmolol à une concentration de 20 à 100 mg/ml, et ladite solution i.V. Est directement administrée au patient. La présente invention concerne également un procédé de production d'une solution i.V. Prête à l'emploi de chlorhydrate d'esmolol par reconstitution d'une poudre constituée de chlorhydrate d'esmolol pur avec un solvant, caractérisé en ce que ledit solvant est un solvant i.V. Dépourvu d'alcool ou d'excipient tampon, en une quantité nécessaire pour obtenir une solution i.V. Prête à l'emploi à une concentration de 20 à 100 mg/ml. La présente invention concerne en outre la solution i.V. Prête à l'emploi contenant une formulation parentérale de 20 à 100 mg/ml de chlorhydrate d'esmolol pur dans un dispositif de perfusion ou consistant en une formulation parentérale de 20 à 100 mg/ml de chlorhydrate d'esmolol pur, d'eau pour injection et/ou de solution saline, et dépourvue de tout alcool ou excipient tampon.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12167443 | 2012-05-10 | ||
| PCT/EP2013/059594 WO2013167657A1 (fr) | 2012-05-10 | 2013-05-08 | Formulation parentérale d'esmolol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37500A1 MA37500A1 (fr) | 2016-03-31 |
| MA37500B1 true MA37500B1 (fr) | 2016-12-30 |
Family
ID=48407551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37500A MA37500B1 (fr) | 2012-05-10 | 2014-11-05 | Formulation parentérale d'esmolol |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US20150087704A1 (fr) |
| EP (1) | EP2846776B1 (fr) |
| JP (1) | JP6220383B2 (fr) |
| CN (1) | CN104379134A (fr) |
| AU (1) | AU2013258031B2 (fr) |
| BR (1) | BR112014027870B1 (fr) |
| CA (1) | CA2872953C (fr) |
| CL (1) | CL2014003028A1 (fr) |
| DK (1) | DK2846776T3 (fr) |
| EA (1) | EA032344B1 (fr) |
| ES (1) | ES2794093T3 (fr) |
| HK (1) | HK1204265A1 (fr) |
| HR (1) | HRP20200897T1 (fr) |
| HU (1) | HUE049314T2 (fr) |
| IL (1) | IL235497A0 (fr) |
| LT (1) | LT2846776T (fr) |
| MA (1) | MA37500B1 (fr) |
| MX (1) | MX2014013556A (fr) |
| MY (1) | MY173900A (fr) |
| NZ (1) | NZ701429A (fr) |
| PH (1) | PH12014502494B1 (fr) |
| PL (1) | PL2846776T3 (fr) |
| PT (1) | PT2846776T (fr) |
| SI (1) | SI2846776T1 (fr) |
| TN (1) | TN2014000464A1 (fr) |
| UA (1) | UA115333C2 (fr) |
| WO (1) | WO2013167657A1 (fr) |
| ZA (1) | ZA201408149B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019122157A1 (fr) * | 2017-12-21 | 2019-06-27 | Ipsol Ag | Lyophilisat comprenant de l'esmolol et de l'adénosine pour une utilisation en cardioplégie |
| CN111848420A (zh) * | 2020-07-22 | 2020-10-30 | 杭州煌森生物科技有限公司 | 一种盐酸艾司洛尔的新晶型及制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6310094B1 (en) * | 2001-01-12 | 2001-10-30 | Baxter International Inc. | Ready-to-use esmolol solution |
| TWI277414B (en) | 2001-01-12 | 2007-04-01 | Baxter Int | Esmolol formulation |
| SE0401842D0 (sv) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| JPWO2007026771A1 (ja) * | 2005-08-31 | 2009-03-12 | 小野薬品工業株式会社 | 点滴用注射剤 |
| US20080293814A1 (en) * | 2007-05-22 | 2008-11-27 | Deepak Tiwari | Concentrate esmolol |
| WO2009079679A2 (fr) | 2007-12-21 | 2009-07-02 | Aop Orphan Pharmaceuticals Ag | Composition pharmaceutique |
| CN102106846A (zh) * | 2009-12-23 | 2011-06-29 | 南京海辰药业有限公司 | 左旋盐酸艾司洛尔药物组合物及其制备方法 |
-
2013
- 2013-05-08 LT LTEP13721740.2T patent/LT2846776T/lt unknown
- 2013-05-08 SI SI201331732T patent/SI2846776T1/sl unknown
- 2013-05-08 AU AU2013258031A patent/AU2013258031B2/en active Active
- 2013-05-08 MY MYPI2014703249A patent/MY173900A/en unknown
- 2013-05-08 DK DK13721740.2T patent/DK2846776T3/da active
- 2013-05-08 EA EA201491841A patent/EA032344B1/ru not_active IP Right Cessation
- 2013-05-08 WO PCT/EP2013/059594 patent/WO2013167657A1/fr active Application Filing
- 2013-05-08 CA CA2872953A patent/CA2872953C/fr active Active
- 2013-05-08 PT PT137217402T patent/PT2846776T/pt unknown
- 2013-05-08 ES ES13721740T patent/ES2794093T3/es active Active
- 2013-05-08 BR BR112014027870-9A patent/BR112014027870B1/pt active IP Right Grant
- 2013-05-08 CN CN201380028099.XA patent/CN104379134A/zh active Pending
- 2013-05-08 UA UAA201413014A patent/UA115333C2/uk unknown
- 2013-05-08 JP JP2015510815A patent/JP6220383B2/ja active Active
- 2013-05-08 HU HUE13721740A patent/HUE049314T2/hu unknown
- 2013-05-08 US US14/398,312 patent/US20150087704A1/en not_active Abandoned
- 2013-05-08 MX MX2014013556A patent/MX2014013556A/es active IP Right Grant
- 2013-05-08 PL PL13721740T patent/PL2846776T3/pl unknown
- 2013-05-08 NZ NZ701429A patent/NZ701429A/en unknown
- 2013-05-08 EP EP13721740.2A patent/EP2846776B1/fr active Active
-
2014
- 2014-10-31 TN TN2014000464A patent/TN2014000464A1/fr unknown
- 2014-11-04 IL IL235497A patent/IL235497A0/en active IP Right Grant
- 2014-11-05 MA MA37500A patent/MA37500B1/fr unknown
- 2014-11-07 PH PH12014502494A patent/PH12014502494B1/en unknown
- 2014-11-07 CL CL2014003028A patent/CL2014003028A1/es unknown
- 2014-11-07 ZA ZA2014/08149A patent/ZA201408149B/en unknown
-
2015
- 2015-05-19 HK HK15104754.1A patent/HK1204265A1/xx unknown
-
2017
- 2017-07-28 US US15/663,645 patent/US20170326095A1/en not_active Abandoned
-
2020
- 2020-06-04 HR HRP20200897TT patent/HRP20200897T1/hr unknown
-
2022
- 2022-01-24 US US17/582,945 patent/US11963940B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200072T1 (hr) | Načini doziranja za spojeve klase ehinokandina | |
| RU2009106862A (ru) | Способы и композиции, повышающие переносимость пациентом методов визуализации миокарда | |
| JP2017519018A5 (fr) | ||
| FI3506886T3 (fi) | Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä | |
| EA201270167A1 (ru) | Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения | |
| EA201370178A1 (ru) | Стабильные составы для парентеральной инъекции пептидных лекарственных средств | |
| FI3581199T3 (fi) | Menetelmiä turvottavan fibroskleroottisen pannikulopatian hoitamiseksi tai vähentämiseksi | |
| EA201691790A1 (ru) | Способ получения продукта глатирамера ацетата | |
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| NZ630346A (en) | Injectable depot formulation comprising optically active tolvaptan and process of producing the same | |
| FI3383385T4 (fi) | Melflufeeniannoskuureja syöpään | |
| RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| MA37500B1 (fr) | Formulation parentérale d'esmolol | |
| PE20130782A1 (es) | Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo | |
| NI201300124A (es) | Los compuestos para el tratamiento y la prevención de la adhesión, las composiciones farmacéuticas relacionados con el compuesto y los métodos para la prevención y el tratamiento de adherencias. | |
| MA40599A1 (fr) | Formulations injectables de paracétamol | |
| EA201291463A1 (ru) | Составы для инфузии лантибиотиков типа b | |
| Raghav et al. | Prospective role of n-acetyl-5-methoxytryptamine and 5-hydroxytryptophan in β-cell health and improved insulin sensitivity in hyperglycemia | |
| RU2013142835A (ru) | Способ лечения ишемического инсульта | |
| RU2014148062A (ru) | Инъекционная фармацевтическая композиция декскетопрофена и трамадола | |
| RU2011101481A (ru) | Способ профилактики острой декомпрессионной болезни | |
| RU2013148539A (ru) | Алиспоривир для лечения инфекции вируса гепатита с | |
| RU2010133699A (ru) | Способ комбинированного лечения глаукомной оптической нейропатии | |
| RU2011112243A (ru) | Способ профилактики системного амилоидоза и его нефропатической формы у экспериментальных животных |